MDxHealth Q1 Revenue Misses Estimates, Company Disputes $10.4M Medicare Recoupment
MDXH is trading near its 52-week low of $1.7 (33% below the low) on elevated volume (11× avg).
Summary
MDxHealth reported Q1 2026 results, with an adjusted loss per share of $0.17, which narrowed from the prior year, and revenue increasing 21.6% year-over-year to $29.55 million. However, the reported revenue fell short of analyst expectations of $30.53 million. The company also confirmed it is disputing a significant $10.4 million Medicare recoupment by contractor Novitas, tied to a retrospective review of historical Resolve MDx claims. This dispute follows yesterday's SEC filing (6-K) which disclosed the company facing this recoupment and exiting its Resolve UTI business. The mixed earnings, particularly the revenue miss, combined with the ongoing material financial dispute, present a challenging outlook for the company. Traders will be closely monitoring the resolution of the Medicare dispute and future financial performance.
At the time of this announcement, MDXH was trading at $1.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.2M. The 52-week trading range was $1.70 to $5.33. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.